ANEBOTCPharmaceutical PreparationsFiscal year ends June 30
Anebulo Pharmaceuticals, Inc.
Financials through Q2 FY2026, quarter ended Dec 31, 2025Last filing: 10-Q on Feb 12, 2026
$0.00+0.00 (+75.00%)
Close on Oct 19, 2026
- Market cap
- $28.76K
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$2.6593 (−99.97%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Dec 31, 2025
Valuation
- Market cap
- $28.76K
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 0.00
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Net income
- -$7.98M
- EPS, diluted
- -$0.19
- Book value per share
- $0.19
- Diluted shares
- 41M
Six years at a glance
Fiscal years 2020 to 2025 and trailing twelve months, USD
Operating income
-$9.10M
Net income
-$7.98M
EPS, diluted
-$0.19
Reported periodTrailing twelve months